


What is claimed is:

1. A compound of the following formula:



wherein

R₁ is a halogenated phenyl;

5 R₂ is nitrogen, phenyl, phenylamide, pyrazole, methylpyrazole, dimethylpyrazole, pyridine, thiophene, dimethylcyclobutyl, dimethylcyclopropyl or cyclopropyl ;

R₃ is benzyl, isopropyl, chlorobenzyl, 2-benzyl-5-methyl-imidazole, methyl thiophene, trifluoro methyl benzyl, 3,5-trifluoromethyl benzyl or ethylmethysulfide; and,

R₄ is NH₂ or OH.

10 2. The compound of Claim 1, wherein R₁ is 3,4-dichlorophenyl.


3. The compound of Claim 1, wherein R₁ is 3-chlorophenyl.

4. The compound of Claim 1, wherein R₄ is OH.

5. A pharmaceutical composition comprising a compound of Claim 1 or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

15

6. A compound of the formula:



wherein

R₁ is a halogenated phenyl;

5 R₂ is bicyclo[2.2.1]heptane, cyclopropane or cyclohexane; and,

R₃ is NH₂, OH or 2-amino-3-phenylpropanamide.

7. The compound of Claim 6, wherein R₁ is 3,4-dichlorophenyl.


8. The compound of Claim 6, wherein R₁ is 3-chlorophenyl.

9. The compound of Claim 6, wherein R₃ is OH.

10 10. The compound of Claim 6, wherein R₃ is 2-amino-3-phenylpropanamide.

11. A pharmaceutical composition comprising a compound of Claim 6 or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

12. A compound of the formula:



wherein

R₁ is a halogenated phenyl;

5 R₂ is (CH₂)_x where x is an integer between 1-4, cyclobutane or dimethylcyclobutane;
and,

R₃ is NH₂ or OH.

13. The compound of Claim 12, wherein R₁ is 3,4-dichlorophenyl.



14. The compound of Claim 12, wherein R₁ is 3-chlorophenyl.

10 15. The compound of Claim 12, wherein R₂ is dimethylcyclobutane.


16. The compound of Claim 12, wherein R₃ is OH.

17. A pharmaceutical composition comprising a compound of Claim 12 or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

18. A compound having a formula selected from the group consisting of:



and,




5 wherein R is a halogenated phenyl.

19. The compound of Claim 18, wherein R is 3,4-dichlorophenyl.

20. The compound of Claim 18, wherein R is 3-chlorophenyl.

21. A pharmaceutical composition comprising a compound of Claim 18 or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

22. A method for inhibiting protein prenylation comprising contacting an isoprenoid transferase with a compound of the formula:



or a pharmaceutically-acceptable salt thereof, wherein

R₁ is a halogenated phenyl;

5 R₂ is nitrogen, phenyl, phenylamide, pyrazole, methylpyrazole, dimethylpyrazole, pyridine, thiophene, dimethylcyclobutyl, dimethylcyclopropyl or cyclopropyl;

R₃ is benzyl, isopropyl, chlorobenzyl, 2-benzyl-5-methyl-imidazole, methyl thiophene, trifluoro methyl benzyl, 3,5-trifluoromethyl benzyl or ethylmethysulfide; and,

R₄ is NH₂ or OH.

10 23. The method of Claim 22, wherein R₁ is 3,4-dichlorophenyl.

24. The method of Claim 22, wherein R₁ is 3-chlorophenyl.

25. The method of Claim 22, wherein R₄ is OH.

26. The method of Claim 22, wherein the step of contacting comprises contacting the compound with an isoprenoid transferase in a cell of an animal having a condition selected from the group
15 consisting of cancer, restenosis, psoriasis, endometriosis, atherosclerosis, ischemia, myocardial ischemic disorders, elevated serum cholesterol levels, angiogenesis, viral infection, fungal infection, yeast infection, bacterial infection, protozoa infection and corneal neovascularization.

27. The method of Claim 22, wherein the step of contacting comprises contacting said compound with an isoprenoid transferase in a cell of a plant having a condition selected from the group consisting of yeast infection and viral infection.


28. The method of Claim 22, wherein said compound inhibits farnesyl-protein transferase.

5 29. The method of Claim 22, wherein said compound modulates geranylgeranyl protein-transferase Type I.

30. The method of Claim 29, wherein said compound has an IC_{50} value of about 60nM or less.

31. The method of Claim 22, wherein said compound modulates geranylgeranyl-protein transferase Type II.

32. A method for inhibiting protein prenylation comprising contacting an isoprenoid transferase with a compound of the formula:



or a pharmaceutically-acceptable salt thereof, wherein

- 5 R_1 is a halogenated phenyl;
 R_2 is bicyclo[2.2.1]heptane, cyclopropane or cyclohexane; and,
 R_3 is NH_2 , OH or 2-amino-3-phenylpropanamide.

33. The method of Claim 32, wherein R_1 is 3,4-dichlorophenyl.

34. The method of Claim 32, wherein R_1 is 3-chlorophenyl.

10 35. The method of Claim 32, wherein R_3 is OH.

36. The method of Claim 32, wherein R_3 is 2-amino-3-phenylpropanamide.

37. The method of Claim 32, wherein the step of contacting comprises contacting the compound with an isoprenoid transferase in a cell of an animal having a condition selected from the group consisting of cancer, restenosis, psoriasis, endometriosis, atherosclerosis, ischemia, myocardial
 15 ischemic disorders, elevated serum cholesterol levels, angiogenesis, viral infection, fungal infection, yeast infection, bacterial infection, protozoa infection and corneal neovascularization.

38. The method of Claim 32, wherein the step of contacting comprises contacting said compound with an isoprenoid transferase in a cell of a plant having a condition selected from the group consisting of yeast infection and viral infection.


39. The method of Claim 32, wherein said compound inhibits farnesyl-protein transferase.

5 40. The method of Claim 32, wherein said compound modulates geranylgeranyl-protein transferase Type I.

41. The method of Claim 40, wherein said compound has an IC_{50} value of about 60nM or less.

42. The method of Claim 32, wherein said compound modulates geranylgeranyl-protein transferase Type II.

43. A method for inhibiting protein prenylation comprising contacting an isoprenoid transferase with a compound of the formula:



or a pharmaceutically-acceptable salt thereof, wherein

5 R₁ is a halogenated phenyl;

 R₂ is (CH₂)_x where x is an integer between 1-4, cyclobutane or dimethylcyclobutane;
and,

 R₃ is NH₂ or OH.

44. The method of Claim 43, wherein R₁ is 3,4-dichlorophenyl.

10 45. The method of Claim 43, wherein R₁ is 3-chlorophenyl.

46. The method of Claim 43, wherein R₂ is dimethylcyclobutane.

47. The method of Claim 43, wherein R₃ is OH.

48. The method of Claim 43, wherein the step of contacting comprises contacting the compound with an isoprenoid transferase in a cell of an animal having a condition selected from the group
15 consisting of cancer, restenosis, psoriasis, endometriosis, atherosclerosis, ischemia, myocardial ischemic disorders, elevated serum cholesterol levels, angiogenesis, viral infection, fungal infection, yeast infection, bacterial infection, protozoa infection and corneal neovascularization.

49. The method of Claim 43, wherein the step of contacting comprises contacting said compound with an isoprenoid transferase in a cell of a plant having a condition selected from the group consisting of yeast infection and viral infection.


50. The method of Claim 43, wherein said compound inhibits farnesyl-protein transferase.

5 51. The method of Claim 43, wherein said compound modulates geranylgeranyl-protein transferase Type I.


52. The method of Claim 51, wherein said compound has an IC_{50} value of about 60nM or less.

53. The method of Claim 43, wherein said compound modulates geranylgeranyl-protein transferase Type II.


54. A method for inhibiting protein prenylation comprising contacting an isoprenoid transferase with a compound having a formula selected from the group consisting of:



,



and,



5

or a pharmaceutically-acceptable salt thereof, wherein R is a halogenated phenyl.

55. The method of Claim 54, wherein R is 3,4-dichlorophenyl.

56. The method of Claim 54, wherein R is 3-chlorophenyl.

57. The method of Claim 54, wherein the step of contacting comprises contacting the compound with an isoprenoid transferase in a cell of an animal having a condition selected from the group consisting of cancer, restenosis, psoriasis, endometriosis, atherosclerosis, ischemia, myocardial ischemic disorders, elevated serum cholesterol levels, angiogenesis, viral infection, fungal infection, yeast infection, bacterial infection, protozoa infection and corneal neovascularization.

58. The method of Claim 54, wherein the step of contacting comprises contacting said compound with an isoprenoid transferase in a cell of a plant having a condition selected from the group consisting of yeast infection and viral infection.

59. The method of Claim 54, wherein said compound inhibits farnesyl-protein transferase.

60. The method of Claim 54, wherein said compound modulates geranylgeranyl-protein transferase Type I.

61. The method of Claim 60, wherein said compound has an IC_{50} value of about 60nM or less.

62. The method of Claim 54, wherein said compound modulates geranylgeranyl-protein transferase Type II.